SBFM Sunshine Biopharma Inc. - Common stock

NASDAQ · Biotechnology · View on SEC EDGAR ↗
$1.16
Price · Aug 19, 2026
Fundamentals as of May 13, 2026
52W Range
$0–$5
21% of range
Analyst Rating
BUY
7 analysts
Price Target
$56
+4728% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—

SBFM Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$1.16
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$0 – $5

SBFM Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income —
EPS —
Free Cash Flow —
Margins —

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
SBFM
Peer Median

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
SBFM
Peer Median

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
SBFM
Peer Median

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
SBFM
Peer Median

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
SBFM
Peer Median

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
SBFM
Peer Median

SBFM Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 7 analysts
  • Strong Buy 2 28.6%
  • Buy 4 57.1%
  • Hold 1 14.3%
  • Sell 0 0.0%
  • Strong Sell 0 0.0%

12-Month Price Target

1 analysts · 2026-08-15
Median target $56.00 +4727.6%
Mean target $56.00 +4727.6%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
-3.4%
Period EPS Actual EPS Est Surprise
March 31, 2026 $-0.25 — —
Dec. 31, 2025 $-5.40 $-2.75 -2.6%
Sept. 30, 2025 $-1.90 $-1.33 -0.57%
June 30, 2025 $-3.90 $-1.12 -2.8%
Dec. 31, 2024 $-1.00 $0.11 -1.1%
Sept. 30, 2024 $-0.94 $9.18 -10.1%

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
SBFM — — — — — —
GRI $122.9K -0.0 — — -256.3% —
SHPH $4M -0.3 0.00% — -400.1% —
DCOY — -0.0 — — — —
ADTX $343.6K -0.0 -97.6% -1349028.2% -1183.4% 8.4%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Institutional owners (13F)

Institutional activity — Q1 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
3 (-1 vs prior Q) 4 (0 vs prior Q) 2 (+1 vs prior Q) 4 (+2 vs prior Q) +9K

Compared to Q4 2025. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Company insiders 4 insiders · 3 officers · 3 directors

Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Steve N. Slilaty Chief Executive Officer Jan. 6, 2021 A 23,343,461 0 0 $0
Camille Sebaaly CFO/Secretary Jan. 6, 2021 A 23,893,086 0 0 $0
Abderrazzak Merzouki Chief Operating Officer Jan. 6, 2021 A 23,342,500 0 0 $0
Advanomics Corp 10% owner Oct. 10, 2016 J 215,014,224 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only